KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Cash: 2009-2025

Historic Change in Cash for Teva Pharmaceutical Industries (TEVA) over the last 10 years, with Sep 2025 value amounting to $42.0 million.

  • Teva Pharmaceutical Industries' Change in Cash fell 96.04% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 204.30%. This contributed to the annual value of $74.0 million for FY2024, which is 81.17% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Change in Cash of $42.0 million as of Q3 2025, which was down 90.95% from $464.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' Change in Cash's 5-year high stood at $1.1 billion during Q3 2024, with a 5-year trough of -$1.6 billion in Q1 2025.
  • For the 3-year period, Teva Pharmaceutical Industries' Change in Cash averaged around -$57.3 million, with its median value being -$18.0 million (2024).
  • Over the last 5 years, Teva Pharmaceutical Industries' Change in Cash had its largest YoY gain of 410.69% in 2023, and its largest YoY loss of 1,365.38% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Change in Cash (Quarterly) stood at $153.0 million in 2021, then spiked by 276.47% to $576.0 million in 2022, then skyrocketed by 69.62% to $977.0 million in 2023, then slumped by 101.84% to -$18.0 million in 2024, then plummeted by 96.04% to $42.0 million in 2025.
  • Its Change in Cash was $42.0 million in Q3 2025, compared to $464.0 million in Q2 2025 and -$1.6 billion in Q1 2025.